Journal of Bioanalysis & Biomedicine

Telerehabilitation, the delivery of rehabilitation services through telecommunication technology, has emerged as a promising approach to enhance accessibility and efficiency in healthcare delivery. However, its successful implementation is influenced by various factors. This article explores the facilitators and inhibitors impacting the adoption and implementation of telerehabilitation programs. By understanding these factors, stakeholders can devise strategies to optimize the integration of telerehabilitation into clinical practice.

Neuroblastoma is a challenging childhood cancer characterized by its aggressive nature and limited treatment options. The quest for novel therapeutic approaches has led researchers to explore natural compounds with potential anticancer properties. Among these, olive oil components have gained attention for their antioxidant and anti-cancer effects. This article discusses the emerging role of olive oil components as promising antioxidants in neuroblastoma treatment. It explores the mechanisms underlying their therapeutic effects, reviews preclinical studies, and highlights future directions for research and clinical translation.

Interleukin-1β (IL-1β) is a key cytokine involved in inflammatory processes and pain modulation. Its role in the context of dental procedures, particularly after placement of cement–screw-retained restorations, is gaining attention. This article aims to explore the quantification and influence of IL-1β on pain and inflammatory response post-placement of cement–screw-retained restorations. We discuss the mechanism of action of IL-1β, its association with pain perception and inflammation, and its implications for dental practice. Additionally, we review recent studies investigating IL-1β levels in patients undergoing cement–screw-retained restoration procedures and their correlation with postoperative pain and inflammation. Understanding the role of IL-1β in this context can provide insights into optimizing patient care and improving treatment outcomes.

Chronic Lymphocytic Leukemia (CLL) is a common hematologic malignancy characterized by the accumulation of mature B lymphocytes in the blood, bone marrow, and lymphoid tissues. Historically, the backbone of CLL therapy has been fludarabine-based regimens for fit patients. However, the landscape of CLL treatment has transformed with the emergence of targeted agents, such as B-cell receptor signaling inhibitors and BCL-2 inhibitors. This article reviews the impact of targeted agents on the survival outcomes of CLL patients who are deemed fit for fludarabinebased therapy. It examines clinical trials, real-world evidence, and expert opinions to provide insights into the evolving treatment paradigms and the implications for clinical practice.